Literature DB >> 26526573

Deregulation of miR-1, miR486, and let-7a in cytogenetically normal acute myeloid leukemia: association with NPM1 and FLT3 mutation and clinical characteristics.

Samaneh Sadat Seyyedi1, Masoud Soleimani2, Marjan Yaghmaie3, Monireh Ajami2, Mansoureh Ajami2, Shahram Pourbeyranvand4, Kamran Alimoghaddam3, Seyed Mohammad Akrami5.   

Abstract

Cytogenetically normal acute myeloid leukemia (CN-AML) constitutes the largest subgroup of AML patients that is associated with molecular alteration. MiRNAs have been shown to be aberrantly expressed in CN-AML. In addition, specific miRNA (miR) expression patterns were found to be associated with certain genetic alterations in these patients. This study investigated the expression level of miR-1, miR-486, and let-7a in 45 CN-AML patients well characterized for FLT3 and/or NPM1 mutations using real-time quantitative RT-PCR and evaluated the association between candidate miRs expression and clinical features. Our data revealed that miR-1 was significantly overexpressed in CN-AML patients, and increasing expression of miR-1 correlated with NPM1 mutation (P < 0.05) and lower hemoglobin level was also observed in patients with miR-1 overexpression (P < 0.05). The expression of miR-1 was much higher in AML-M2 compared with other subtypes. Further, we found significantly increasing miR-486 expression in 40 of 45 (89 %) CN-AML patients. There was no significant association of upregulation of miR-486 with clinical parameters. The expression level of miR-486 was increased in AML-M2 subtype. The levels of let-7a were significantly increased in CN-AML patients compared to the healthy control and significantly higher in the NPM1 ± CN-AML patients. There was no correlation detected between the level of let-7a and FLT3+. An increasing expression level of let-7a was demonstrated in M2 subtype. In addition, our data showed no significant association between increasing let-7a and clinical characteristic. Comparison of peripheral blood and bone marrow results in 30 CN-AML patients showed that there is a considerable concordance between PB and BM in the results of candidate miR levels (P < 0.001). In conclusion, further studies should also be performed to detect functional mechanism of these miRs.

Entities:  

Keywords:  Cytogenetically normal AML; let-7a; miR-1; miR-486

Mesh:

Substances:

Year:  2015        PMID: 26526573     DOI: 10.1007/s13277-015-4289-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  33 in total

1.  Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients.

Authors:  Guido Marcucci; Kati S Maharry; Klaus H Metzeler; Stefano Volinia; Yue-Zhong Wu; Krzysztof Mrózek; Deedra Nicolet; Jessica Kohlschmidt; Susan P Whitman; Jason H Mendler; Sebastian Schwind; Heiko Becker; Ann-Kathrin Eisfeld; Andrew J Carroll; Bayard L Powell; Jonathan E Kolitz; Ramiro Garzon; Michael A Caligiuri; Richard M Stone; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2013-05-06       Impact factor: 44.544

2.  Detection of nucleophosmin 1 mutations by quantitative real-time polymerase chain reaction versus capillary electrophoresis: a comparative study.

Authors:  Fareed H Barakat; Rajyalakshmi Luthra; C Cameron Yin; Bedia A Barkoh; Seema Hai; Waqar Jamil; Yaminiben I Bhakta; Su Chen; L Jeffrey Medeiros; Zhuang Zuo
Journal:  Arch Pathol Lab Med       Date:  2011-08       Impact factor: 5.534

Review 3.  Molecular genetics in acute myeloid leukemia.

Authors:  Ulrike Bacher; Susanne Schnittger; Torsten Haferlach
Journal:  Curr Opin Oncol       Date:  2010-11       Impact factor: 3.645

4.  C/EBPA gene mutation and C/EBPA promoter hypermethylation in acute myeloid leukemia with normal cytogenetics.

Authors:  Ying Lu; Wengang Chen; Wei Chen; Anthony Stein; Lawrence M Weiss; Qin Huang
Journal:  Am J Hematol       Date:  2010-06       Impact factor: 10.047

5.  EVI1 controls proliferation in acute myeloid leukaemia through modulation of miR-1-2.

Authors:  M Gómez-Benito; A Conchillo; M A García; I Vázquez; M Maicas; C Vicente; I Cristobal; N Marcotegui; L García-Ortí; E Bandrés; M J Calasanz; M M Alonso; M D Odero
Journal:  Br J Cancer       Date:  2010-09-14       Impact factor: 7.640

6.  Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.

Authors:  Ramiro Garzon; Michela Garofalo; Maria Paola Martelli; Roger Briesewitz; Lisheng Wang; Cecilia Fernandez-Cymering; Stefano Volinia; Chang-Gong Liu; Susanne Schnittger; Torsten Haferlach; Arcangelo Liso; Daniela Diverio; Marco Mancini; Giovanna Meloni; Robin Foa; Massimo F Martelli; Cristina Mecucci; Carlo M Croce; Brunangelo Falini
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-28       Impact factor: 11.205

7.  Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors.

Authors:  Kristin Pietschmann; Hella Anna Bolck; Marc Buchwald; Steffi Spielberg; Harald Polzer; Karsten Spiekermann; Gesine Bug; Thorsten Heinzel; Frank-Dietmar Böhmer; Oliver H Krämer
Journal:  Mol Cancer Ther       Date:  2012-08-31       Impact factor: 6.261

8.  Overexpressed let-7a-3 is associated with poor outcome in acute myeloid leukemia.

Authors:  Yun Li; Jiang Lin; Jing Yang; Jun Qian; Wei Qian; Dong-Ming Yao; Zhao-Qun Deng; Qing Liu; Xing-Xing Chen; Dong Xie; Cui An; Chun-Yan Tang
Journal:  Leuk Res       Date:  2013-09-30       Impact factor: 3.156

9.  MicroRNA-486-5p is an erythroid oncomiR of the myeloid leukemias of Down syndrome.

Authors:  Lital Shaham; Elena Vendramini; Yubin Ge; Yaron Goren; Yehudit Birger; Marloes R Tijssen; Maureen McNulty; Ifat Geron; Omer Schwartzman; Liat Goldberg; Stella T Chou; Holly Pitman; Mitchell J Weiss; Shulamit Michaeli; Benjamin Sredni; Berthold Göttgens; John D Crispino; Jeffrey W Taub; Shai Izraeli
Journal:  Blood       Date:  2014-12-22       Impact factor: 22.113

10.  miR-10a is aberrantly overexpressed in Nucleophosmin1 mutated acute myeloid leukaemia and its suppression induces cell death.

Authors:  Adam Bryant; Catalina A Palma; Vivek Jayaswal; Yee Wa Yang; Mark Lutherborrow; David Df Ma
Journal:  Mol Cancer       Date:  2012-02-20       Impact factor: 27.401

View more
  3 in total

1.  MicroRNAs and tRNA-derived fragments predict the transformation of myelodysplastic syndromes to acute myeloid leukemia.

Authors:  Yan Guo; Stephen A Strickland; Sanjay Mohan; Shaoying Li; Amma Bosompem; Kasey C Vickers; Shilin Zhao; Quanhu Sheng; Annette S Kim
Journal:  Leuk Lymphoma       Date:  2017-01-13

2.  PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.

Authors:  Jason A Hanna; Matthew R Garcia; Alicia Lardennois; Patrick J Leavey; Dino Maglic; Alexandre Fagnan; Jonathan C Go; Jordan Roach; Yong-Dong Wang; David Finkelstein; Mark E Hatley
Journal:  Oncogene       Date:  2018-01-25       Impact factor: 9.867

Review 3.  Genetics of blood malignancies among Iranian population: an overview.

Authors:  Majid Ghayour-Mobarhan; Amir Sadra Zangouei; Seyed Mohammad Hosseinirad; Majid Mojarrad; Meysam Moghbeli
Journal:  Diagn Pathol       Date:  2020-05-06       Impact factor: 2.644

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.